Viewpoint compares costs and access to GLP-1 receptor agonists for weight loss across four countries, suggesting disparities.
This Viewpoint compares use and costs of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss between the US and 3 other peer countries.
No takes yet. Share an insight, caveat, or question.
Vokinger et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: